Slide 1: Fourth Quarter 2022 Operating & Financial Results Conference Call
Fourth Quarter 2022 Operating & Financial Results Conference Call / Webinar March 20th, 2023 4:30 PM Eastern Time NASDAQ :LTRN
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements r
Slide 3: Contents, Speakers, Host
Contents Speakers Host 01 Introduction Panna Sharma Chief Executive Officer, 02 Q4 2022 Highlights President and Director 03 Starlight Therapeutics David Margrave 04 Scientific Highlights Chief Financial Officer Nicole Leber Investor Relations 05 Financial Highlights Kishor Bhatia 05 Q&A Chief Scien
Slide 4: Using AI, Lantern is Transforming Drug Discovery Timelines and Cost
Using AI, Lantern is Transforming Drug Discovery Timelines and Cost Lantern has launched 9 programs in two years, and is anticipating launching Multiple Phase 1 trials in 2023 Lantern’s Drug Development Model Large Scale/Multi-omics Proprietary AI Accelerated timeline Oncology Data platform RADR® an
Slide 5: Lantern's Diverse & Unique AI Driven Pipeline of Drug Programs
Lantern’s Diverse & Unique AI Driven Pipeline of Drug Programs Lantern has 12 disclosed drug programs including an ADC program and the Phase 2 Harmonic™ trial Program Indication Discovery Optimization Preclinical Pre IND Phase I Phase II LP-300 Non-Small Cell Lung Cancer (NSCLC) LP-100 Homologous Re
Slide 6: Fourth Quarter 2022 Highlights
Fourth Quarter 2022 Highlights LP-300 and Harmonic™ Trial LP-184 for Solid Tumors • Activated five clinical trial sites, across twelve locations • IND enabling studies completed (NY, CA, IL, OH, TX) • Filing of IND application anticipated in Q2 2023 • First patients anticipated in early Q2 2023 • Ph
Slide 7: Starlight Therapeutics' CNS and Brain Cancer Programs Born from Billions of Datapoints and AI
Starlight Therapeutics’ CNS and Brain Cancer Programs were Born from Billions of Datapoints and AI There are over 120 types of central nervous system (CNS) and brain cancers and a majority 5 Year Survival have no effective treatment options Rates of CNS And Brain Cancers • No effective single-agent
Slide 8: Multiple Clinical Trials are Planned for STAR-001
Multiple Clinical Trials are Planned for STAR-001 ADULT CNS CANCERS Discovery Preclinical IND Enabling Phase 1A Phase 2 Phase 3 STAR-001 has Multi-billion Glioblastoma (GBM) Market Potential In CNS Cancers Other High-Grade Gliomas (HGG) Phase 1A will be $5-6 billion (USD) conducted by Global Annual
Slide 9: The Harmonic Trial for Never Smoker Patients with NSCLC
The Harmonic™ Trial for Never Smoker Patients with NSCLC Major Updates Additional Value Drivers • Activated 5 sites across 12 different • First of its kind iPhone app launched for the Harmonic™ trial locations in the US • The new Harmonic™ trial app provides patients, caregivers, and the cancer comm
Slide 10: LP-184 has Potent Efficacy Across Multiple Solid Tumors
LP-184 has Potent Efficacy Across Multiple Solid Tumors Solid Tumors $6-7 billion Program Highlights DDR Deficient Tumors Global annual market potential • Unique Mechanism of Action: Including: • Synthetic lethality Pancreatic Cancer • Overexpression of PTGR1 LP-184 • Bladder Cancer • • Deficiencies
Slide 11: LP-184 has a Unique Mechanism of Action Leveraging Synthetic Lethality
LP-184 has a Unique Mechanism of Action Leveraging Synthetic Lethality Genetic factors contributing to LP-184's Synthetic Lethality Synthetic Lethality for LP-184 KOL Webinar on Synthetic Lethality Dr. Zoltan Szallasi, M.D. Register: https://bit.ly/3J84Zui Principal investigator at Danish Cancer Soc
Slide 12: LP-284 Developed from RADR Insights to Late-Stage IND Enabling Studies
LP-284 was Developed from RADR® Insights to Late-Stage IND Enabling Studies in Less Than 2 Years for Non-Hodgkin’s Lymphomas LP-284 for non-Hodgkin’s B-cell lymphomas $1.2 billion Mantle Cell Lymphoma LP-284 • U.S. & Europe • Double Hit Lymphoma annual market potential Program Highlights • LP-284 ha
Slide 13: RADR is Lantern's AI and Machine-Learning Platform
RADR® is Lantern’s AI and Machine-Learning Platform that Powers Oncology Drug Discovery and Development Response Algorithm for Drug Positioning & Rescue A proprietary integrated data analytics, experimental biology, oncology-focused, machine-learning-based platform focused on drug development 80%+ 4
Slide 14: RADR's Library of Over 200+ Advanced Algorithms
RADR®’s Library of Over 200+ Advanced Algorithms Powers its Multi-Faceted Modules Example RADR® Algorithms Ensemble Deep Learning Bayesian Based Tree Based Rule Based Clustering Others Examples Regression • Predicting drug sensitivity values, e.g. IC50 Supervised Learning • Predicting blood brain ba
Slide 15: RADR's Capabilities Enhanced with Focus on Antibody Drug Conjugates
RADR®’s Capabilities Enhanced with Increased Focus on the Development of Antibody Drug Conjugates What are Antibody Drug Conjugates (ADCs)? Antibody Drug Conjugates (ADCs) are highly specific cancer-targeted antibodies linked to potent anti-tumor small molecules and designed for the treatment of can
Slide 16: Lantern's Collaborators are Leveraging RADR to Accelerate Drug Candidates
Lantern’s Collaborators are Leveraging RADR® to Accelerate the Development of their Drug Candidates Actuate Therapeutics, Inc. is a private clinical stage TTC Oncology is an emerging biotechnology company founded biopharmaceutical company focused on the in 2015. TTC Oncology’s mission is to develop
Slide 17: LP-184 Phase 1A Clinical Trial Updates and Design
LP-184Clinical ClinicalTrial Trial Updates Schema: and Design of Phase 1A Trial LP-184 Phase IA LP-184 LP-184 Phase 1A Clinical Trial Updates and Design LP-184 DL1* (n=1) • Anticipated Phase 1A Clinical Trial Dates • IND enabling studies completed LP-184 DL2 Accelerated • IND application submission
Slide 18: LP-284 Demonstrates Stronger Anti-Tumor Potential in Mouse Models
LP-284 Treatment Demonstrates Stronger Anti-Tumor Potential in Mouse Models Compared to Current MCL Therapies LP-284 Significantly Decreases MCL Tumor Volumes in LP-284 Increases Probability of Survival in Mice Mice vs Standard of Care Agents vs Standard of Care Agents A. B. 17
Slide 19: Summary Results of Operations
Summary Results of Operations Three Months Ended Year Ended December 31, December 31, (Unaudited) 2022 2021 2022 2021 Operating expenses: General and administrative $ 1,574,680 $ 1,348,983 $ 5,829,799 $ 5,020,928 Research and development 2,251,598 2,162,260 8,602,954 7,570,580 Total operating expens
Slide 20: Balance Sheet Highlights & Summary
Balance Sheet Highlights & Summary December 31, 2022 December 31, 2021 Cash and Marketable Securities $55,196,085 $70,725,447 Prepaid Expenses & Other Current Assets $2,985,472 $1,990,953 Total Assets $58,836,321 $73,950,477 Total Liabilities $2,798,297 $2,379,057 Total Stockholders’ Equity $56,038,
Slide 21: Shares Outstanding
Shares Outstanding December 31, 2022 LANTERN PHARMA INC. (LTRN) Common Shares Outstanding 10,857,040 Warrants 177,998 Options (Employees, Management and Directors) 1,037,591 Fully Diluted Shares Outstanding 12,072,629 20 27
Slide 22: 2023 Objectives
2023 Objectives A Transformational year for Lantern ● Advance enrollment of The Harmonic™ Trial & increase patient/clinician awareness ● Launch clinical trials for LP-184 and LP-284 ● Progress LP-184 (STAR-001) towards Ph. 1 / 2 pediatric clinical trial, including ATRT ● Advance ADC preclinical deve
Slide 23: Nasdaq: LTRN www.lanternpharma.com @LanternPharma
IR Contact: IR@lanternpharma.com 1-972-277-1136 Nasdaq: LTRN www.lanternpharma.com @LanternPharma Sign up for the Spark Newsletter www.lanternpharma.com/media/newsletter#subscriptionSec CONNECT WITH US Fourth Quarter 2022 Earnings 22